{"id":"abobotulinumtoxina-dose-1","safety":{"commonSideEffects":[{"rate":"null","effect":"Eyelid ptosis"},{"rate":"null","effect":"Eyelid drooping"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Dry eye"},{"rate":"5-10%","effect":"Eye irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by blocking the release of acetylcholine, a neurotransmitter that stimulates muscle contraction. This results in a reduction in muscle spasms and an improvement in muscle tone. The effects are typically temporary and reversible.","oneSentence":"AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscles to reduce muscle spasms and improve muscle tone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:25.374Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glabellar lines"},{"name":"Frown lines"},{"name":"Crows feet"}]},"trialDetails":[{"nctId":"NCT07489430","phase":"PHASE2","title":"DaxibotulinumtoxinA for Blepharospasm","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-07-01","conditions":"Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid","enrollment":20},{"nctId":"NCT06583343","phase":"PHASE4","title":"Effect of Botulinum Toxin on Selective Motor Control and Pain in Diplegic Cerebral Palsy","status":"COMPLETED","sponsor":"Gaziosmanpasa Research and Education Hospital","startDate":"2022-06-25","conditions":"Cerebral Palsy Spastic Diplegia","enrollment":40},{"nctId":"NCT07452510","phase":"NA","title":"Comparison of Dry Needling and Two Botulinum Toxins for Bruxism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Recep Tayyip Erdogan University","startDate":"2026-01-09","conditions":"Bruxism, Sleep Bruxism, Adult, Awake Bruxism","enrollment":69},{"nctId":"NCT07440173","phase":"PHASE4","title":"Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Spasticity as Sequela of Stroke","enrollment":60},{"nctId":"NCT06047457","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-09-29","conditions":"Episodic Migraine","enrollment":751},{"nctId":"NCT06047444","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-10-12","conditions":"Chronic Migraine","enrollment":759},{"nctId":"NCT04752774","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.","status":"RECRUITING","sponsor":"Ipsen","startDate":"2021-04-29","conditions":"Spasticity","enrollment":240},{"nctId":"NCT07388927","phase":"PHASE4","title":"A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A","status":"NOT_YET_RECRUITING","sponsor":"DKSH Management (Thailand) Limited","startDate":"2026-02","conditions":"Ecchymosis After Periorbital Rejuvenation With Botulinum Toxin Type A, Crow's Feet Lines, Lateral Canthal Lines, LCL","enrollment":48},{"nctId":"NCT06585696","phase":"PHASE3","title":"A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)","status":"COMPLETED","sponsor":"Cutia Therapeutics（Wuxi）Co.,Ltd","startDate":"2024-06-11","conditions":"Glabellar Frown Lines","enrollment":554},{"nctId":"NCT07360483","phase":"NA","title":"Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-01-01","conditions":"Hypertrophic Scars","enrollment":48},{"nctId":"NCT02816151","phase":"PHASE3","title":"Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2011-02","conditions":"Neurogenic Vesical Hyperactivity Syndrom","enrollment":29},{"nctId":"NCT06070987","phase":"NA","title":"Exoskeleton Robotic Assisted Gait Training in Spastic Stroke Post Botulinum Toxin A Injection","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":"Spastic Gait, Spastic","enrollment":30},{"nctId":"NCT07335367","phase":"PHASE2","title":"PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-09","conditions":"Androgenetic Alopecia (AGA)","enrollment":76},{"nctId":"NCT04821089","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines","status":"RECRUITING","sponsor":"Ipsen","startDate":"2021-04-06","conditions":"Moderate to Severe Upper Facial Lines","enrollment":727},{"nctId":"NCT07270042","phase":"NA","title":"Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection","status":"NOT_YET_RECRUITING","sponsor":"Tishreen University","startDate":"2025-12-01","conditions":"Hyperactive Masseter Muscle","enrollment":20},{"nctId":"NCT07268261","phase":"NA","title":"Combined Method of Surgical Treatment of Anal Fissure","status":"RECRUITING","sponsor":"State Scientific Centre of Coloproctology, Russian Federation","startDate":"2023-09-01","conditions":"Chronic Anal Fissure","enrollment":122},{"nctId":"NCT04936542","phase":"PHASE4","title":"A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-06-23","conditions":"Upper Limb Spasticity","enrollment":464},{"nctId":"NCT06834789","phase":"PHASE1","title":"A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-02-18","conditions":"Glabellar Lines","enrollment":132},{"nctId":"NCT05123053","phase":"PHASE2","title":"Firdapse for Post-BOTOX Vocal Weakness","status":"COMPLETED","sponsor":"Augusta University","startDate":"2021-10-28","conditions":"Vocal Weakness(Post-BOTOX Injection)","enrollment":18},{"nctId":"NCT07025044","phase":"","title":"Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections","status":"RECRUITING","sponsor":"Alexis Dieter","startDate":"2025-09-03","conditions":"Overactive Bladder (OAB), Urge Incontinence","enrollment":40},{"nctId":"NCT06349733","phase":"EARLY_PHASE1","title":"A Dosage-dependent Manner of Botulinum Toxin Type A on the Prevention of Postoperative Scars of Various Anatomic Regions of the Body","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-03-23","conditions":"Scar","enrollment":50},{"nctId":"NCT05100199","phase":"PHASE2","title":"A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-10-06","conditions":"Glabellar Lines","enrollment":328},{"nctId":"NCT05565950","phase":"PHASE1, PHASE2","title":"AI-09 In Subjects With Glabellar Lines, GL-101","status":"COMPLETED","sponsor":"Eirion Therapeutics Inc.","startDate":"2022-09-03","conditions":"Glabellar Frown Lines","enrollment":72},{"nctId":"NCT06137287","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-11-22","conditions":"Masseter Muscle Prominence","enrollment":259},{"nctId":"NCT07124806","phase":"NA","title":"Comparison of Two Botox Injection Techniques to Improve Gait","status":"COMPLETED","sponsor":"Universidad de los Andes, Chile","startDate":"2022-07-01","conditions":"Muscle Spasticity, Stroke Sequelae, Spasticity as Sequela of Stroke","enrollment":18},{"nctId":"NCT06794866","phase":"PHASE3","title":"A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-01-22","conditions":"Forehead Lines","enrollment":150},{"nctId":"NCT03848143","phase":"PHASE2","title":"Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain","status":"COMPLETED","sponsor":"Isabel Moreno Hay","startDate":"2019-09-11","conditions":"Neuropathic Pain","enrollment":10},{"nctId":"NCT07072806","phase":"PHASE4","title":"A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2022-06-14","conditions":"Forehead Rhytides","enrollment":20},{"nctId":"NCT05152576","phase":"PHASE2","title":"A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-11-29","conditions":"Forehead Lines","enrollment":124},{"nctId":"NCT05874154","phase":"NA","title":"Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-01-02","conditions":"Post Stroke Seizure, Spastic Foot","enrollment":60},{"nctId":"NCT05089357","phase":"","title":"Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2021-11-11","conditions":"Glabellar Lines","enrollment":250},{"nctId":"NCT05013424","phase":"PHASE2","title":"A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-09-01","conditions":"Glabellar Lines","enrollment":92},{"nctId":"NCT05327972","phase":"PHASE2","title":"DEgenerative ROtator Cuff Disease and Botulinum TOXin","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-01-20","conditions":"Degenerative Rotator Cuff Disease","enrollment":60},{"nctId":"NCT03887377","phase":"PHASE2, PHASE3","title":"The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2019-06-10","conditions":"Scar, Hypertrophic Scar, Mammary Disorder","enrollment":22},{"nctId":"NCT03654066","phase":"PHASE4","title":"Botox or Botox With Esophageal Dilation in Patients With Achalasia","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2019-05-13","conditions":"Achalasia","enrollment":50},{"nctId":"NCT04075981","phase":"PHASE3","title":"Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-09-30","conditions":"Cardiac Surgery","enrollment":220},{"nctId":"NCT06946160","phase":"PHASE3","title":"A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Espad Pharmed","startDate":"2024-05-28","conditions":"Glabellar Lines, Glabellar Frown Lines","enrollment":146},{"nctId":"NCT05141006","phase":"PHASE2","title":"Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-03-29","conditions":"Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)","enrollment":83},{"nctId":"NCT06953271","phase":"PHASE4","title":"Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","status":"NOT_YET_RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-15","conditions":"Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)","enrollment":164},{"nctId":"NCT06941636","phase":"PHASE3","title":"Botulinumtoxin A as a Treatment for Myalgia and Myofacial Pain in Patient With Temporomandibulardisorders","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2025-05-01","conditions":"Temporomandibular Disorder","enrollment":90},{"nctId":"NCT06481475","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines","status":"RECRUITING","sponsor":"Chongqing Claruvis Pharmaceutical Co., Ltd.","startDate":"2025-01-09","conditions":"Moderate to Severe Glabellar Lines","enrollment":174},{"nctId":"NCT06886750","phase":"PHASE4","title":"The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2025-03-30","conditions":"Cervical Dystonia, Primary","enrollment":45},{"nctId":"NCT06840158","phase":"PHASE3","title":"Double-blind Comparative Randomized Multicenter","status":"COMPLETED","sponsor":"Innopharm LLC","startDate":"2021-10-15","conditions":"Cerebral Palsy (CP)","enrollment":80},{"nctId":"NCT06839118","phase":"PHASE3","title":"Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache","status":"RECRUITING","sponsor":"Danish Headache Center","startDate":"2025-01-10","conditions":"Posttraumatic Headache","enrollment":80},{"nctId":"NCT06796855","phase":"PHASE4","title":"Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections","status":"COMPLETED","sponsor":"Bagcilar Training and Research Hospital","startDate":"2023-02-01","conditions":"Overactive Bladder Syndrome, Refractory Overactive Bladder","enrollment":60},{"nctId":"NCT06387329","phase":"PHASE4","title":"Bladder Botox UTI Antibiotic Prophylaxis","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2024-04-04","conditions":"Overactive Bladder, Bladder Pain Syndrome","enrollment":100},{"nctId":"NCT02969356","phase":"PHASE4","title":"Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2016-12-18","conditions":"Spastic Hemiparesis","enrollment":157},{"nctId":"NCT05720065","phase":"PHASE2","title":"Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2023-09-20","conditions":"Temporomandibular Disorders","enrollment":50},{"nctId":"NCT05769478","phase":"PHASE1","title":"Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2023-09-15","conditions":"Botulism, Iatrogenic Botulism","enrollment":21},{"nctId":"NCT05605756","phase":"PHASE4","title":"BOTOX Effects on Seizure Severity and Susceptibility","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-03-01","conditions":"Drug-resistant Focal Seizure","enrollment":3},{"nctId":"NCT06755099","phase":"PHASE2, PHASE3","title":"Female Sexual Dysfunction Assessment and Managment of Vaginismus","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-01-01","conditions":"Female Sexual Dysfunction","enrollment":40},{"nctId":"NCT04985916","phase":"PHASE2","title":"ET-01 in Subjects With Lateral Canthal Lines, LCL-210","status":"COMPLETED","sponsor":"Eirion Therapeutics Inc.","startDate":"2021-07-19","conditions":"Lateral Canthal Lines, LCL, Crow's Feet","enrollment":280},{"nctId":"NCT05072821","phase":"PHASE4","title":"Botulinum Toxin Type a Injection to Prevent Keloid Recurrence","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-10-13","conditions":"Scar Keloid","enrollment":28},{"nctId":"NCT05773053","phase":"PHASE2","title":"A Study of NT 201 Doses in the Treatment of Platysma Prominence","status":"COMPLETED","sponsor":"Merz Aesthetics GmbH","startDate":"2023-03-22","conditions":"Platysma Prominence","enrollment":73},{"nctId":"NCT04819360","phase":"PHASE4","title":"Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis","status":"TERMINATED","sponsor":"Brigitte Schürch","startDate":"2021-06-01","conditions":"Urinary Bladder, Neurogenic, Multiple Sclerosis","enrollment":1},{"nctId":"NCT05320393","phase":"PHASE2","title":"Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2022-03-30","conditions":"Glabellar Frown Lines","enrollment":154},{"nctId":"NCT06583551","phase":"NA","title":"Effectiveness of Botox, Dry Needling, Pharmacological Treatment, and Manual Therapy for Bruxism-Induced Myalgia","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2021-01-03","conditions":"Myalgia, Bruxism, Quality of Life","enrollment":80},{"nctId":"NCT06583486","phase":"PHASE3","title":"A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing Claruvis Pharmaceutical Co., Ltd.","startDate":"2024-03-19","conditions":"Moderate to Severe Glabellar Lines","enrollment":488},{"nctId":"NCT05797220","phase":"","title":"The Efficacy of Botulinum Toxin Alone Versus Combined Botulinum Toxin and Topical Diltiazem in Chronic Anal Fissure","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2016-11-04","conditions":"Anal Fissure Chronic","enrollment":217},{"nctId":"NCT05426161","phase":"PHASE4","title":"The Effect of Subcutaneous Injection of Botulinum Toxin A on Chronic Wound Pain in Lower Extremities","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2023-02-07","conditions":"Chronic Pain, Lower Extremity Wound","enrollment":10},{"nctId":"NCT05956509","phase":"PHASE1","title":"Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity","status":"TERMINATED","sponsor":"AbbVie","startDate":"2024-01-12","conditions":"Upper Limb Spasticity","enrollment":1},{"nctId":"NCT06385171","phase":"","title":"Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation","status":"RECRUITING","sponsor":"Global Aesthetics LLC","startDate":"2024-05-22","conditions":"Wrinkle","enrollment":500},{"nctId":"NCT05606757","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2024-05-07","conditions":"Ventral Hernia, Abdominal Hernia","enrollment":""},{"nctId":"NCT03779841","phase":"PHASE2","title":"Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-03-01","conditions":"Post-Operative Atrial Fibrillation","enrollment":323},{"nctId":"NCT06225024","phase":"NA","title":"Efficacy of Extracorporeal Shock Wave Therapy on Spasticity","status":"COMPLETED","sponsor":"Kayseri City Hospital","startDate":"2022-03-15","conditions":"Stroke, Spasticity, Muscle","enrollment":40},{"nctId":"NCT06230146","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-05-01","conditions":"Keloid","enrollment":45},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":"Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence","enrollment":100},{"nctId":"NCT03806933","phase":"PHASE2","title":"Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Aesthetics GmbH","startDate":"2019-01-23","conditions":"Moderate to Severe Glabellar Frown Lines","enrollment":241},{"nctId":"NCT03508921","phase":"PHASE4","title":"Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-07-01","conditions":"Overactive Bladder, Urinary Tract Infections","enrollment":22},{"nctId":"NCT03712449","phase":"PHASE4","title":"A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-01-22","conditions":"Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality","enrollment":59},{"nctId":"NCT06013644","phase":"EARLY_PHASE1","title":"Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-06-03","conditions":"Myofascial Trigger Point Pain, Myofascial Pain Syndrome","enrollment":39},{"nctId":"NCT02177617","phase":"PHASE4","title":"Neurotoxin and Physical Therapy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-12","conditions":"Cervical Dystonia","enrollment":16},{"nctId":"NCT04736745","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.","status":"TERMINATED","sponsor":"Ipsen","startDate":"2021-02-10","conditions":"Moderate Upper Facial Lines, Severe Upper Facial Lines","enrollment":56},{"nctId":"NCT03911102","phase":"PHASE2","title":"Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-03-11","conditions":"Lateral Canthal Lines","enrollment":63},{"nctId":"NCT05585398","phase":"PHASE1","title":"A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2022-10-19","conditions":"N/A, as no Specific Medical Condition Will be Treated","enrollment":40},{"nctId":"NCT05057117","phase":"PHASE4","title":"Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis","status":"COMPLETED","sponsor":"Merete Haedersdal","startDate":"2021-09-27","conditions":"Hyperhidrosis Primary Focal Axilla","enrollment":30},{"nctId":"NCT03915067","phase":"PHASE2","title":"BOTOX® for the Treatment of Platysma Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-04-23","conditions":"Platysma Prominence","enrollment":171},{"nctId":"NCT05309564","phase":"NA","title":"Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter","status":"COMPLETED","sponsor":"Region Västerbotten","startDate":"2020-03-01","conditions":"Bite Force, Botulinum Toxins, Type A","enrollment":32},{"nctId":"NCT05127018","phase":"PHASE1, PHASE2","title":"Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-11-20","conditions":"Smiling, Botulinum Toxins, Type A","enrollment":33},{"nctId":"NCT05617118","phase":"","title":"BTA vs Baclofen for Pelvic Myofascial Pain Syndrome","status":"UNKNOWN","sponsor":"Saint Petersburg State University, Russia","startDate":"2022-12-01","conditions":"Chronic Pain, Chronic Pelvic Pain Syndrome, Myofascial Pain Syndrome","enrollment":52},{"nctId":"NCT04815967","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity","status":"UNKNOWN","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2021-11-16","conditions":"Spasticity, Cerebrovascular Accident, Multiple Sclerosis","enrollment":272},{"nctId":"NCT04099667","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity","status":"UNKNOWN","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2019-12-17","conditions":"Spasticity","enrollment":272},{"nctId":"NCT03786770","phase":"PHASE2","title":"Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-01-24","conditions":"Frown Lines","enrollment":61},{"nctId":"NCT05605886","phase":"EARLY_PHASE1","title":"Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-05-20","conditions":"Myofacial Pain Syndrome, Botulinum Toxin","enrollment":24},{"nctId":"NCT02097121","phase":"PHASE3","title":"OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05-23","conditions":"Urinary Incontinence, Urinary Bladder, Overactive","enrollment":56},{"nctId":"NCT05651256","phase":"PHASE2, PHASE3","title":"Efficacy of Botulinum Toxin in Temporomandibular Disorders","status":"COMPLETED","sponsor":"University of Salamanca","startDate":"2021-03-01","conditions":"Temporomandibular Joint Disorder Bilateral","enrollment":20},{"nctId":"NCT05618470","phase":"PHASE2, PHASE3","title":"Wumeiwan Jiawei Fang Use in Patients With Blepharospasm","status":"UNKNOWN","sponsor":"China Academy of Chinese Medical Sciences","startDate":"2018-01-12","conditions":"Dry Eye Syndromes, Meige Syndrome, Blepharospasm","enrollment":80},{"nctId":"NCT03236012","phase":"PHASE1","title":"Hyperhidrosis in Patients With Amputations-Botox","status":"COMPLETED","sponsor":"University of Utah","startDate":"2019-01-08","conditions":"Hyperhidrosis","enrollment":25},{"nctId":"NCT01251380","phase":"PHASE3","title":"Dysport® Pediatric Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-10","conditions":"Cerebral Palsy, Muscle Spasticity, Children","enrollment":216},{"nctId":"NCT02353871","phase":"PHASE3","title":"Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-01","conditions":"Moderate to Severe Glabellar Lines","enrollment":185},{"nctId":"NCT01251367","phase":"PHASE3","title":"Dysport® Adult Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-06","conditions":"Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury","enrollment":352},{"nctId":"NCT01313312","phase":"PHASE3","title":"Dysport® Adult Upper Limb Spasticity Extension Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-11","conditions":"Nervous System Disorders","enrollment":258},{"nctId":"NCT01357980","phase":"PHASE2","title":"Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-05","conditions":"Detrusor Muscle Hyperactivity","enrollment":47},{"nctId":"NCT01333397","phase":"PHASE2","title":"Safety and Efficacy Study of Dysport RU and Glabellar Lines","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-03","conditions":"Glabellar Frown Lines","enrollment":176},{"nctId":"NCT04080882","phase":"PHASE2","title":"Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2019-09-25","conditions":"Platysmal Bands","enrollment":80},{"nctId":"NCT03736928","phase":"PHASE2","title":"Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2018-11-26","conditions":"Glabellar Frown Lines","enrollment":401},{"nctId":"NCT03839693","phase":"PHASE2","title":"ET-01 in Subjects With Lateral Canthal Lines, LCL-208","status":"COMPLETED","sponsor":"Eirion Therapeutics Inc.","startDate":"2018-10-16","conditions":"Lateral Canthal Lines, Crow's Feet","enrollment":75},{"nctId":"NCT04277247","phase":"PHASE2, PHASE3","title":"Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2021-01-12","conditions":"Dystonia Disorder, Parkinson Disease","enrollment":40},{"nctId":"NCT05340439","phase":"PHASE2","title":"INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2022-06","conditions":"Spastic Cerebral Palsy","enrollment":30},{"nctId":"NCT03326856","phase":"PHASE2","title":"ET-01 in Subjects With Lateral Canthal Lines","status":"COMPLETED","sponsor":"Eirion Therapeutics Inc.","startDate":"2017-10-25","conditions":"Lateral Canthal Lines, Crow's Feet","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AbobotulinumtoxinA dose 1","genericName":"AbobotulinumtoxinA dose 1","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Biologic","firstApprovalDate":"","aiSummary":"AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscles to reduce muscle spasms and improve muscle tone. Used for Glabellar lines, Frown lines, Crows feet.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}